To investigate the combinational activity beyond breast cancer models, the activity of ABBV-176 and Veliparib was evaluated in two HCC models, HepG2 and HuH-7 LOT, that express low levels of PRLR (0.09x and 0.26x total PRLR levels in MCF7, respectively). The gene discussed is PRLR; the disease is breast cancer.